BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Onartuzumab: Phase Ib started

Roche disclosed in its 3Q13 earnings that it began an open-label, international Phase Ib trial to evaluate onartuzumab every 21 days alone or in combination with 400 mg oral sorafenib...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >